Source: Business Wire

Press Release: Synthekine : Synthekine Doses First Patient in Phase 1 Clinical Trial of Orthogonal IL-2 and CD19 CAR-T Combination Therapy, STK-009 + SYNCAR-001, for Treatment of CD19+ Hematologic Malignancies

MENLO PARK, Calif.--(BUSINESS WIRE)--Synthekine Doses 1st Patient in Ph. 1 Trial of Orthogonal IL-2 & CD19 CAR-T Combo Therapy, STK-009 + SYNCAR-001, for CD19+ Hematologic Malignancies

Read full article »
Synthekine's Competitors | Synthekine's News | Synthekine's Financials
Stay up-to-date with the latest news on Synthekine
Est. Annual Revenue
$100K-5.0M
Est. Employees
25-100
Debanjan Ray's photo - President & CEO of Synthekine

President & CEO

Debanjan Ray

CEO Approval Rating

90/100

Read more
Stay up-to-date with the latest news on Synthekine